Koyanagi, Yoshio

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports

CRISPR and Genetic EngineeringHIV Research and Treatment

Cited by 565

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports

SARS-CoV-2 and COVID-19 Researchinterferon and immune responses

Cited by 433

Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line

Yamamoto, N., Okada, M., Koyanagi, Y., Kannagi, M., & Hinuma, Y. (1982) · Science

T-cell and Retrovirus StudiesViral-associated cancers and disorders

Cited by 398

Cell-to-cell infection by HIV contributes over half of virus infection

Iwami, S., Takeuchi, J. S., Nakaoka, S., Mammano, F., Clavel, F., Inaba, H., Kobayashi, T., Misawa, N., Aihara, K., Koyanagi, Y., et al. (2015) · eLife

HIV Research and TreatmentMathematical and Theoretical Epidemiology and Ecology Models

Cited by 161

Increased HTLV‐I proviral DNA in HTLV‐I–associated myelopathy: A quantitative polymerase chain reaction study

Kira, J., Koyanagi, Y., Yamada, T., Itoyama, Y., Goto, I., Yamamoto, N., Sasaki, H., & Sakaki, Y. (1991) · Annals of Neurology

T-cell and Retrovirus StudiesInfectious Diseases and Tuberculosis

Cited by 152

De Novo Human T-Cell Leukemia Virus Type 1 Infection of Human Lymphocytes in NOD-SCID, Common γ-Chain Knockout Mice

Miyazato, P., Yasunaga, J.-I., Taniguchi, Y., Koyanagi, Y., Mitsuya, H., & Matsuoka, M. (2006) · Journal of Virology

T-cell and Retrovirus StudiesViral-associated cancers and disorders

Cited by 54